Dianthus Therapeutics (NASDAQ:DNTH) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Dianthus Therapeutics (NASDAQ:DNTH) issued its quarterly earnings data on Tuesday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05), FiscalAI reports. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 25.73% and a negative net margin of 10,096.95%.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded down $3.04 during midday trading on Thursday, hitting $109.46. The company had a trading volume of 179,028 shares, compared to its average volume of 973,500. The company has a 50 day moving average of $94.02 and a 200 day moving average of $79.98. The stock has a market capitalization of $5.98 billion, a P/E ratio of -26.38 and a beta of 1.22. Dianthus Therapeutics has a 52-week low of $18.08 and a 52-week high of $114.55.

Insiders Place Their Bets

In related news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 87,779 shares of company stock valued at $7,985,235. 3.02% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the second quarter worth $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter valued at about $40,000. Russell Investments Group Ltd. bought a new stake in shares of Dianthus Therapeutics in the third quarter worth about $64,000. Tower Research Capital LLC TRC lifted its position in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DNTH has been the subject of several recent analyst reports. Wedbush boosted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.64.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.